Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Parikh on the Future of Oncology: AI, Data, and Patients at the Center
2
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
3
The Future of AI-Driven Clinical Decisions in Oncology
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5